Whole-Body [<sup>18</sup>F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease

Whole-Body [<sup>18</sup>F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease

The 2-deoxy-d-[<sup>18</sup>F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) is widely utilized to assess the vascular and articular inflammatory burden of patients with a suspected diagnosis of rheumatic disease. We aimed to elucidate the impact of [<...

Full description

Bibliographic Details
Main Authors:	Matthias Fröhlich, Sebastian Serfling, Takahiro Higuchi, Martin G. Pomper, Steven P. Rowe, Marc Schmalzing, Hans-Peter Tony, Michael Gernert, Patrick-Pascal Strunz, Jan Portegys, Eva-Christina Schwaneck, Ottar Gadeholt, Alexander Weich, Andreas K. Buck, Thorsten A. Bley, Konstanze V. Guggenberger, Rudolf A. Werner
Format:	Article
Language:	English
Published:	MDPI AG 2021-11-01
Series:	Diagnostics
Subjects:	giant cell arteritis GCA [<sup>18</sup>F]FDG PET/CT vasculature inflammation polymyalgia rheumatica
Online Access:	https://www.mdpi.com/2075-4418/11/11/2073

Similar Items

An Atypical Case of Vasculitis: When ‘Occult’ 18FDG-PET Scan Findings Create a Classification Dilemma
by: Elena Lopez-Francos, et al.
Published: (2019-12-01)

The Sport’s Bar Grandpa: an unusual left temporo-mandibular and tongue pain
by: Paolo Leandri, et al.
Published: (2014-09-01)

Non-Invasive Metabolic and Structural Retinal Markers in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Cross-Sectional Study
by: Simon J. Lowater, et al.
Published: (2022-09-01)

Possible giant cell arteritis symptoms are common in newly diagnosed patients with Polymyalgia Rheumatica: results from an incident primary care PMR cohort
by: William Masson, et al.
Published: (2017-12-01)

Did the first description of patients with polymyalgia rheumatica take place in Scotland or in Denmark?
by: C. Manzo, et al.
Published: (2024-03-01)

Presence of subclinical giant cell arteritis in patients with morning stiffness of duration less than 45 minutes at the time of diagnosis of polymyalgia rheumatica
by: Ciro Manzo, et al.
Published: (2024-01-01)

Use of 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients affected by polymyalgia rheumatica and persistent increase of acute phase reactants
by: Michele Colaci, et al.
Published: (2022-11-01)

Large-vessel giant cell arteritis: A rare cause of stroke
by: Himanshu Pathak, et al.
Published: (2017-01-01)

Giant cell arteritis: is the clinical spectrum of the disease changing?
by: Miguel Á. González-Gay, et al.
Published: (2019-07-01)

Does low risk of infections as a marker of effective immunity predict increased risk of subsequent giant cell arteritis or polymyalgia rheumatica? A Danish population-based case–control study
by: Brault C, et al.
Published: (2018-10-01)

Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica
by: Kornelis S. M. van der Geest, et al.
Published: (2022-06-01)

Low incidence of malignancy in patients with suspected polymyalgia rheumatica or giant cell arteritis, examined with FDG-PET/CT
by: Tanja Fromberg Gorlen, et al.
Published: (2024-02-01)

Post-COVID-19 and Post-COVID-19 Vaccine Arthritis, Polymyalgia Rheumatica and Horton’s Arteritis: A Single-Center Assessment of Clinical, Serological, Genetic, and Ultrasonographic Biomarkers
by: Francesca Bandinelli, et al.
Published: (2023-12-01)

Predictive Factors of Giant Cell Arteritis in Polymyalgia Rheumatica Patients
by: André Ramon, et al.
Published: (2022-12-01)

CURRENT VIEW OF HORTON'S DISEASE: ANALYSIS OF ITS CASES IN THE KHABAROVSK TERRITORY
by: E. N. Otteva, et al.
Published: (2011-06-01)

Aberrant phenotype of circulating antigen presenting cells in giant cell arteritis and polymyalgia rheumatica
by: Rosanne D. Reitsema, et al.
Published: (2023-08-01)

Central retinal vein oclussion as presentation of giant cell arteritis and polymyalgia rheumatica. Case report.
by: Jersson Camilo Sanchez-Gamez, et al.
Published: (2022-05-01)

Polymyalgia rheumatica in the 2018–2020 clinical guidelines. Part I. At-risk groups, adjuvant therapy
by: О.G. Puzanovа
Published: (2020-11-01)

Widespread headache as the first clinical manifestation of giant cell arteritis in patients affected by polymyalgia rheumatica
by: Ciro Manzo
Published: (2016-11-01)

European Headache Federation recommendations for neurologists managing giant cell arteritis
by: S. P. Mollan, et al.
Published: (2020-03-01)

Presentaties van polymyalgia rheumatica bij oudere patienten
by: Rianne Lindeboom, et al.
Published: (2015-06-01)

Contribution of the new 2012 EULAR/ACR classification criteria for the diagnosis of polymyalgia rheumatica
by: F. Muratore, et al.
Published: (2018-03-01)

Perspectives and unmet needs in polymyalgia rheumatica. Providing the fundamental framework for the development of new treatment regimes in polymyalgia rheumatica
by: B.D. Nielsen, et al.
Published: (2018-03-01)

Tuberculosis masquerading as polymyalgia rheumatica
by: Kamal Kishore Pandita, et al.
Published: (2015-01-01)

Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitides—Cross-Sectional Baseline Analysis of the Prospective Rh-GIOP Cohort
by: Andriko Palmowski, et al.
Published: (2022-02-01)

Comorbidities in polymyalgia rheumatica: a systematic review
by: Richard Partington, et al.
Published: (2018-11-01)

Normal ESR, CRP and Platelet Count in Giant Cell Arteritis and Polymyalgia Rheumatica: A Diagnostic Conundrum
by: Abdullahi Elsheikh Mahgoub, et al.
Published: (2022-02-01)

Improved Workflow for Analysis of Vascular Myocyte Time-Series and Line-Scan Ca<sup>2+</sup> Imaging Datasets
by: Madison Boskind, et al.
Published: (2023-06-01)

[<sup>18</sup>F]FDG PET/CT in Large Vessel Vasculitis: The Impact of Expertise and Confounders on Image Analysis
by: Lidija Antunovic, et al.
Published: (2022-11-01)

18F-fluorodeoxyglucose–positron emission tomography/computed tomography for the diagnosis of polymyalgia-like illnesses: a retrospective study
by: Hideyuki Horikoshi, et al.
Published: (2020-04-01)

Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey
by: Pierre-André Jarrot, et al.
Published: (2024-12-01)

Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography in Diagnosing Polymyalgia Rheumatica and Large-Vessel Vasculitis: A Case-Control Study
by: Anne Desvages, et al.
Published: (2023-04-01)

Prevalence of Newly Diagnosed Malignancies in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis, Comparison of 18F-FDG PET/CT Scan with Chest X-ray and Abdominal Ultrasound: Data from a 40 Week Prospective, Exploratory, Single Centre Study
by: Amir Emamifar, et al.
Published: (2020-12-01)

Biomarkers in the era of targeted therapy in giant cell arteritis and polymyalgia rheumatica: is it possible to replace acute-phase reactants?
by: Guillermo Carvajal Alegria, et al.
Published: (2023-06-01)

Damage to extracranial arteries in giant cell arteritis according to PET/CT
by: E. E. Filatova, et al.
Published: (2023-03-01)

Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica
by: Yannick van Sleen, et al.
Published: (2019-08-01)

Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations
by: Sebastian Unizony, et al.
Published: (2021-01-01)

Systemic vasculitis in the geriatric population
by: Ari Stiel Radu Halpern
Published: (2008-03-01)

The role of the general practitioner and the out-of-hospital public rheumatologist in the diagnosis and follow-up of patients with polymyalgia rheumatica
by: A. Sobrero, et al.
Published: (2018-03-01)

The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity
by: Montecucco Carlomaurizio, et al.
Published: (2011-05-01)